Cargando…
Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease that affects the upper and lower motor neurons. Currently, the only treatment for ALS is riluzole, which only has a limited effect on increasing survival from 3 to 6 months. New therapies are needed in the clinica...
Autores principales: | Ortiz, Juan Fernando, Khan, Sawleha Arshi, Salem, Amr, Lin, Zayar, Iqbal, Zafar, Jahan, Nusrat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645306/ https://www.ncbi.nlm.nih.gov/pubmed/33173626 http://dx.doi.org/10.7759/cureus.10818 |
Ejemplares similares
-
Fecal Microbiota Transplantation in Recurrent Clostridium Difficile Infection: Is it Superior to Other Conventional Methods?
por: Lin, Zayar, et al.
Publicado: (2020) -
How to Treat Asymptomatic and Symptomatic Urinary Tract Infections in the Kidney Transplant Recipients?
por: Iqbal, Zafar, et al.
Publicado: (2020) -
Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review
por: Neupane, Purushottam, et al.
Publicado: (2023) -
Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
por: Al-Chalabi, Ammar, et al.
Publicado: (2021) -
Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis
por: Jayasinghe, Maleesha, et al.
Publicado: (2022)